BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pye A, Turner AM. Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. Expert Opin Investig Drugs 2019;28:891-902. [PMID: 31550938 DOI: 10.1080/13543784.2019.1672656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Belchamber KBR, Walker EM, Stockley RA, Sapey E. Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:3183-92. [PMID: 33311976 DOI: 10.2147/COPD.S276792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Mcnulty MJ, Silberstein DZ, Kuhn BT, Padgett HS, Nandi S, Mcdonald KA, Cross CE. Alpha-1 antitrypsin deficiency and recombinant protein sources with focus on plant sources: Updates, challenges and perspectives. Free Radical Biology and Medicine 2021;163:10-30. [DOI: 10.1016/j.freeradbiomed.2020.11.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Santos G, Turner AM. Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Fac Rev 2020;9:1. [PMID: 33659933 DOI: 10.12703/b/9-1] [Reference Citation Analysis]
4 Wang C, Zhao P, Sun S, Teckman J, Balch WE. Leveraging Population Genomics for Individualized Correction of the Hallmarks of Alpha-1 Antitrypsin Deficiency. Chronic Obstr Pulm Dis 2020;7:224-46. [PMID: 32726074 DOI: 10.15326/jcopdf.7.3.2019.0167] [Reference Citation Analysis]
5 Miravitlles M, Nuñez A, Torres-durán M, Casas-maldonado F, Rodríguez-hermosa JL, López-campos JL, Calle M, Rodríguez E, Esquinas C, Barrecheguren M. The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2020;17:346-54. [DOI: 10.1080/15412555.2020.1795824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lior Y, Jasevitch M, Ochayon DE, Zaretsky M, Lewis EC, Aharoni A. Application of directed evolution and back-to-consensus algorithms to human alpha1-antitrypsin leads to diminished anti-protease activity and augmented anti-inflammatory activities. Cell Immunol 2020;355:104135. [PMID: 32703529 DOI: 10.1016/j.cellimm.2020.104135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Lo Bello F, Hansbro PM, Donovan C, Coppolino I, Mumby S, Adcock IM, Caramori G. New drugs under development for COPD. Expert Opinion on Emerging Drugs 2020;25:419-31. [DOI: 10.1080/14728214.2020.1819982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Quinn M, Ellis P, Pye A, Turner AM. Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives. Ther Clin Risk Manag 2020;16:1243-55. [PMID: 33364772 DOI: 10.2147/TCRM.S234377] [Reference Citation Analysis]